Overview

Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India

Status:
Recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
Existing problem with DR TB management: Injectable regimens for longer duration with toxicity Poor adherence, treatment failures, continued transmission Need of the study: Oral regimens of shorter duration Improved treatment adherence Implementation of community-based models of care Reduction in direct costs and indirect costs of patients Improved treatment outcomes Need for shorter, tolerable and effective regimen Hence modified BPaL regimen is designed to study the newer shorter oral in varying doses of Linezolid for pre XDR Tb patients and MDR TI/NR patients
Phase:
Phase 3
Details
Lead Sponsor:
Tuberculosis Research Centre, India
Collaborators:
BJ Medical College, Ahmedabad
Govt. Medical College, Surat
International Union Against Tuberculosis and Lung Diseases
KGMU, Lucknow
NITRD, New Delhi
RBIPMT, Delhi
Sarvodaya Charitable Trust Hospital, Ghatkopar, Mumbai
Shatabdi Centenary Hospital, Govandi, Mumbai
SN Medical College, Agra
Treatments:
Bedaquiline
Linezolid